W. Brian Dalton

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index2.0kcitations112works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(25), Acute Myeloid Leukemia Research(24), Microtubule and mitosis dynamics(22), Cancer-related Molecular Pathways(18), Acute Lymphoblastic Leukemia research(12)

Publications112 total

Targeting <i>EZH2</i> Oncogenic Splicing: Decoding the Regulatory Network and Antisense Correction
2026Open Access
Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms
Blood·2025Open Access
DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors
Blood·2025· 1 citedOpen Access
Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques
Blood·2025Open Access
Distinct and convergent effects of <i>SF3B1</i> mutations in human breast cancer
Proceedings of the National Academy of Sciences·2025Open Access
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities
Leukemia Research·2025Open Access
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Blood Neoplasia·2025· 1 citedOpen Access
Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML
2025Open Access
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy
Haematologica·2025· 1 citedOpen Access
Abstract 483: RNA-missplicing dependent nucleic acid therapeutics for SF3B1-mutant cancers
Cancer Research·2025
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma
Hepatology·2024· 7 citedOpen Access
Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
Blood·2024Open Access
Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias
Blood·2024· 1 citedOpen Access
PSAT1 Suppression Drives a Targetable Serine Dependence in AML
Blood·2024Open Access
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts
Blood Advances·2024· 7 citedOpen Access
Outcome heterogeneity of &lt;i&gt;TP53&lt;/i&gt;-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Haematologica·2023· 11 citedOpen Access
An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes
Haematologica·2023· 6 citedOpen Access
Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia
Leukemia Research·2023· 7 cited
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts
2023· 1 citedOpen Access
Data from &lt;i&gt;ESR1&lt;/i&gt; Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Gabriel Ghiaur(20), Lukasz P. Gondek(19), Amy E. DeZern(19), Mark J. Levis(17), Ivana Gojo(14), Jonathan Webster(14), Gabrielle T. Prince(13), Alexander J. Ambinder(11), Vincent W. Yang(10), Tania Jain(10), David Chu(9), Daniel J. Zabransky(9), Karen Cravero(9), Ben Ho Park(9), B. Douglas Smith(9), Richard J. Jones(9), Theodoros Karantanos(8), Kelly Kyker‐Snowman(7), Berry Button(7), Josh Lauring(7)